| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
REGENSBURG, Germany—Via its German subsidiary Applied Biosystems Deutschland GmbH,  Carlsbad, Calif.-based Life Technologies Corp., has announced the purchase of 58 percent of the outstanding shares in GeneArt AG. As a result, Life Technologies is now the majority shareholder in this Regensburg, Germany-based gene synthesis and protein production company.

The founders of GeneArt, Dr. Ralf Wagner, Dr. Hans Wolf, Dr. Marcus Graf, and individual members of the management—as well as the venture capital companies EquiNet EarlyStage Capital and S-REFIT AG, signed contracts in early April with Applied Biosystems Deutschland GmbH for selling their GeneArt shares.

Life Technologies is planning a voluntary public tender offer for the remaining GeneArt shares.

As Rachel Lehmann-Haupt noted in an article at BNET, this is the second  major announcement this business quarter to put Life Technologies "in a solid leadership position in the gene sequencing race," both in the United States and Europe.

The first, she noted, was a partnership with the Ignite Institute for Individualized Health to create a sequencing center in the United States, wherein Ignite acquired 100 of the company's Applied Biosystems SOLiD Systems, which they plan to use for research on cancer, diabetes, neurological disorders such as Alzheimer's, cardiovascular diseases such as myocardial infarction and stroke, and autism spectrum disorders.

Currently, Lehmann-Haupt wrote, two-thirds of the next-generation sequencers in facilities around the world come from Illumina, while 454 Life Sciences and Life Technologies' Applied BioSystems operations together make up 15 percent.  

"Whole-genome sequencing companies are beginning to get more targeted," she noted. "Illumina Inc. and Life Technologies are both gunning for the general sequencing market while 454 Life Sciences, a Roche company, is targeting researchers who are looking for long-read sequencing runs, which will eventually be clinically applied to matching donors for organ transplants. But clearly, this recent news shows that [Life Technologies] is gaining solid ground in gene sequencing."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue